Evidence map›Paper›PMID 31167575›Full record

ArticleExpert opinion on therapeutic targets2019

Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment.

Rajan Patel, Jeffrey I Traylor, Khatri Latha, Amy B Heimberger, Shulin Li, Ganesh Rao

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on therapeutic targets, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. The role of Fibrinogen-like proteins in Cancer.International journal of biological sciences · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rajan Patela Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Jeffrey I Traylora Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Khatri Lathaa Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Amy B Heimbergera Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Shulin Lib Department of Pediatrics-Research , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Ganesh Raoa Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Fgl-2 targeted therapy for reversing multi-modality immune suppressionR01CA203493 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, LI, SHULIN · 2016 to 2020
$1.8M
MODELING MALIGNANT PROGRESSION IN GLIOMAR01NS094615 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RAO, GANESH · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA203493NINDS NIH HHS R01 NS094615
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyAdultAnimalsBrain NeoplasmsFibrinogenGlioblastomaHumansFGL2 protein, humanFibrinogenFGL2glioblastoma multiformelow grade gliomaprogression

Identifiers

PMID31167575
PMCPMC6635074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.